Covalent bonded antithrombogenic polyurethane material

Claim 2

An antithrombogenic polyurethane polymer which comprises: (a) a polyurethane substrate; (b) a polymeric amine selected from the group of a polyvinyl amine, a polyalkylenimine having 2 to 4 carbon atoms per amine unit and mixtures thereof covalently bonded to said polyurethane substrate; and (c) an antithrombogenic agent covalently bonded to said polymeric amine.

Claim 3

The antithrombogenic polyurethane polymer of claim 1 wherein the antithrombogenic material is selected from the group consisting of heparin, prostaglandins, urokinase, streptokinase, sulfated polysaccharide, albumin and mixtures thereof.

Claim 4

The antithrombogenic polyurethane polymer of claim 1 wherein the polyurethane polymer is selected from thermosetting polyurethane polymers and thermoplastic polyurethane polymers.

Claim 5

The antithrombogenic polyurethane polymer of claim 1 wherein the polyalkylenimine is selected from the group consisting of polyethylenimine, polypropylenimine, polybutylenimine and mixtures thereof.

Claim 6

The antithrombogenic polyurethane polymer of claim 1 wherein the polymeric amine has an average molecular weight of at least about 11,000.

Claim 7

The antithrombogenic polyurethane polymer of claim 1 wherein the polymeric amine is covalently bonded to the polyurethane substrate through a polyisocyanate prepolymer.

Claim 8

The antithrombogenic polyurethane polymer of claim 6 wherein the polyisocyanate prepolymer contains 2 to 30% free NCO units.

Claim 9

The antithrombogenic polyurethane polymer of claim 1 wherein the polymeric amine is covalently bonded to the polyurethane substrate through the activation of polyurethane surface functional amine groups.

Claim 10

The antithrombogenic polyurethane polymer of claim 1 wherein the antithrombogenic agent is activated with an activating agent to enable covalent coupling to the polymeric amine.

Claim 11

The antithrombogenic polyurethane polymer of claim 9 wherein the activating agent is selected from the group consisting of N-ethyl-5-phenylisoxazolium-3'-sulfonate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide.

Claim 12

A process for imparting antithrombogenic activity to polyurethane polymer materials, which comprises: (a) treating the surface of the polyurethane polymer material with a solution of a polymeric amine selected from the group consisting of a polyvinyl amine, a polyalkylenimine having 2 to 4 carbon atoms per amine unit and mixtures thereof so that the polymeric amine becomes covalently bonded to said polyurethane substrate, wherein the pH of the polymeric amine solution is at least about 5.0. (b) washing said surface essentially free of any non-covalently bonded polymeric amine; and (c) treat the surface with an activated antithrombogenic agent to covalently bond the antithrombogenic agent to the polymeric amine.

Claim 13

A process for imparting antithrombogenic activity to polyurethane polymer materials, which comprises: (a) treating the surface of the polyurethane polymer material with a solution of a polymeric amine selected from the group consisting of a polyvinyl amine, a polyalkylenimine having 2 to 4 carbon atoms per amine unit and mixtures thereof so that the polymeric amine becomes covalently bonded to said polyurethane substrate, wherein the pH of the polymeric amine solution is at least about 5.0. (b) washing said surface essentially free of any non-covalently bonded polymeric amine; and (c) treat the surface with an activated antithrombogenic agent to covalently bond the antithrombogenic agent to the polymeric amine.

Claim 14

The process of claim 11 wherein the antithrombogenic material is selected from the group consisting of heparin, prostaglandins, urokinase, streptokinase, sulfated polysaccharide, albumin and mixtures thereof.

Claim 15

The process of claim 11 wherein the polyurethane polymer is selected from thermosetting polyurethane polymers and thermoplastic polyurethane polymers.

Claim 16

The process of claim 11 wherein the polyalkylenimine is selected from the group consisting of polyethylenimine, polypropylenimine, polybutylenimine and mixtures thereof.

Claim 17

The process of claim 11 wherein the polymeric amine has an average molecular weight of at least about 11,000.

Claim 18

The process of claim 11 wherein the polymeric amine is covalently bonded to the polyurethane substrate through a polyisocyanate prepolymer.

Claim 19

The process of claim 16 wherein the polyisocyanate prepolymer contains 2 to 30% free NCO units.

Claim 20

The process of claim 11 wherein the polymeric amine is covalently bonded to the polyurethane substrate through the activation of polyurethane surface functional amine groups.

Claim 21

The process of claim 18 wherein activation of the polyurethane substrate is achieved by testing the polyurethane surface with concentrated hydrochloric acid.

Claim 22

The process in claim 11 wherein the pH of the polymeric amine solution is from about 5.0 to about 12.0.

Claim 23

The process of claim 20 wherein the pH of the polymeric amine solution is from about 7.0 to about 9.0.

Claim 24

The process of claim 11 wherein the antithrombogenic agent is activated with an activating agent to enable covalent coupling to the polyamine.

Claim 25

The process of claim 22 wherein the activating agent is selected from the group consisting of N-ethyl-5-phenylisoxazolium-3'-sulfonate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide.